acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
ORPHA: 1023812 Treatments Available
Available Treatments (2)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Dexrazoxane Orphan | IV infusion, 500mg vial for reconstitution | FDA Approved | 6 | 7d |
| Azacitidine Orphan Cold Chain | Subcutaneous injection, 100mg vial; IV infusion | FDA Approved | 8 | 5d |
Classification & Codes
Orphanet Code
ORPHA:102381acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
| Orphanet | ORPHA:102381 |
| Treatments | 2 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO